公开(公告)号：US08461114B2

公开(公告)日：2013-06-11

申请号：US12780065

申请日：2010-05-14

申请人： Lin Mei ,  Yanmei Tao ,  Wen-Chen Xiong

发明人： Lin Mei ,  Yanmei Tao ,  Wen-Chen Xiong

IPC分类号： A61K38/00

CPC分类号： C07K14/4702 ,  C07K16/32 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/14

摘要： Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.

摘要翻译： 调节ErbB2和Erbin之间的相互作用是治疗ErbB2介导的疾病的一种或多种症状的有效方法。 已经发现Erbin在体内稳定ErbB2并且抑制Erbin和ErbB2之间异源二聚体的形成相对于对照水平降低或抑制ErbB2的生物学活性。 降低ErbB2的生物活性可用于治疗以ErbB2的过表达或失调为特征的病症。 这些病症包括但不限于乳腺癌和前列腺癌。 或者，促进或增强Erbin与ErbB2相互作用的Erbin激动剂可用于治疗某些神经障碍。 还发现Erbin在周围神经系统神经元的髓鞘形成中起作用。

公开(公告)号：US20100291077A1

公开(公告)日：2010-11-18

申请号：US12780065

申请日：2010-05-14

申请人： Lin Mei ,  Yanmei Tao ,  Wen-Chen Xiong

发明人： Lin Mei ,  Yanmei Tao ,  Wen-Chen Xiong

IPC分类号： A61K39/395 ,  C12N5/02 ,  A61P35/00

CPC分类号： C07K14/4702 ,  C07K16/32 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/14

摘要： Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.

摘要翻译： 调节ErbB2和Erbin之间的相互作用是治疗ErbB2介导的疾病的一种或多种症状的有效方法。 已经发现Erbin在体内稳定ErbB2并且抑制Erbin和ErbB2之间异源二聚体的形成相对于对照水平降低或抑制ErbB2的生物学活性。 降低ErbB2的生物活性可用于治疗以ErbB2的过表达或失调为特征的病症。 这些病症包括但不限于乳腺癌和前列腺癌。 或者，促进或增强Erbin与ErbB2相互作用的Erbin激动剂可用于治疗某些神经障碍。 还发现Erbin在周围神经系统神经元的髓鞘形成中起作用。

公开(公告)号：US20100260774A1

公开(公告)日：2010-10-14

申请号：US12740594

申请日：2008-11-03

申请人： Wen-Cheng Xiong ,  Jae-Ho Lee ,  Lin Mei

发明人： Wen-Cheng Xiong ,  Jae-Ho Lee ,  Lin Mei

IPC分类号： A61K38/02 ,  C07K16/18 ,  A61K39/395 ,  A61K31/7088 ,  A61K31/713 ,  A61K31/711 ,  A61K31/7105 ,  C07H21/04 ,  C07H21/02 ,  A61P15/18 ,  A61P15/16 ,  A61P15/08 ,  C12Q1/02

CPC分类号： A61K38/18 ,  G01N33/689 ,  G01N2333/475 ,  G01N2800/367

摘要： Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.

摘要翻译： 提供男性或女性避孕方法和组合物。 组合物包括有效量的netrin-1以减少或抑制雄性精液中的精子浓度或抑制或减少雄性配子与女性受试者的雌性配子的融合。另一个实施方案提供了一种通过确定雌性不育症的量来确定男性不育症的量 的netrin-1在附睾液或精液样本中的比较，将来自可能的男性的附睾液或精液样品中的netting-1与netrin-1的水平进行比较，其中netrin-1 在男性受试者的样本中，来自可育男性样本中的netrin-1水平高于或低于男性受试者的男性不育症。

公开(公告)号：US20120039881A1

公开(公告)日：2012-02-16

申请号：US13278417

申请日：2011-10-21

申请人： Lin Mei ,  Wen-Cheng Xiong ,  Ran-Sook Woo ,  Xiaoming Li

发明人： Lin Mei ,  Wen-Cheng Xiong ,  Ran-Sook Woo ,  Xiaoming Li

IPC分类号： A61K39/395 ,  A61K38/18 ,  A61K39/00 ,  A61P25/22 ,  A61P25/18 ,  A61P25/08 ,  A61P25/24 ,  A61K38/45 ,  A61P25/00

CPC分类号： A61K39/3955 ,  A61K38/177 ,  A61K38/1883 ,  A61K38/45

摘要： Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject.

摘要翻译： 提供了用于调节受试者中GABA释放的方法和组合物。 优选的实施方案提供含有有效量的ErbB4配体的组合物以增强或促进GABA释放，即GABA能传递。 根据待治疗的病症，ErbB4配体可以是激动剂配体或拮抗剂配体。 还提供了治疗神经障碍的方法。 可以治疗的代表性疾病包括但不限于精神分裂症，癫痫，抑郁和焦虑，失眠，中风，疼痛，双相，孤独症或其组合。 通过增加GABA释放可以在受试者中诱导镇静作用。 还提供了在受试者中诱导刺激作用的方法。 在这些方法中，向受试者施用有效量的ErbB4拮抗剂配体以减少或抑制受试者中的GABA释放。

公开(公告)号：US07688540B1

公开(公告)日：2010-03-30

申请号：US11957616

申请日：2007-12-17

申请人： Lin Mei ,  Xiaokun L. Chew ,  Teik EE Yeo

发明人： Lin Mei ,  Xiaokun L. Chew ,  Teik EE Yeo

IPC分类号： G11B20/20

CPC分类号： G11B20/20 ,  G11B5/024 ,  G11B5/5534 ,  G11B20/1217 ,  G11B2020/1282 ,  G11B2220/2516

摘要： A disk drive is disclosed comprising a disk and a head actuated radially over the disk. The head is positioned over a first radial location, and a first data tracks per inch (TPI—1) is selected for data tracks recorded near the first radial location. The head is positioned over a second radial location, and a second data tracks per inch (TPI—2) is selected for data tracks recorded near the second radial location. The head is positioned over a third radial location, and a third data tracks per inch (TPI—3) is selected for data tracks recorded near the third radial location. A geometry of the head is estimated in response to TPI—1, TPI—2 and TPI—3.

摘要翻译： 公开了一种磁盘驱动器，包括盘和在盘上径向地致动的磁头。 头部位于第一径向位置上，并且为在第一径向位置附近记录的数据轨道选择每英寸第一数据轨迹（TPI-1）。 头部位于第二径向位置上，并且对于在第二径向位置附近记录的数据轨道选择每英寸第二数据轨迹（TPI-2）。 头部位于第三径向位置上，并且为在第三径向位置附近记录的数据轨道选择每英寸第三数据轨道（TPI-3）。 根据TPI-1，TPI-2和TPI-3估计头部的几何形状。

公开(公告)号：US09244082B2

公开(公告)日：2016-01-26

申请号：US13452018

申请日：2012-04-20

申请人： Lin Mei ,  Wen-Cheng Xiong ,  Bin Zhang ,  Chengyong Shen

发明人： Lin Mei ,  Wen-Cheng Xiong ,  Bin Zhang ,  Chengyong Shen

IPC分类号： A61K39/395 ,  A61K38/00 ,  C07K1/00 ,  G01N33/68 ,  C12Q1/68 ,  G01N33/564 ,  G01N33/92

CPC分类号： G01N33/6896 ,  C07K16/28 ,  C07K2317/76 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/564 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/705 ,  G01N2500/04 ,  G01N2800/28 ,  G01N2800/38

摘要： The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

摘要翻译： 本发明包括用于检测神经传递或发育障碍的方法，包括但不限于对乙酰胆碱受体（AChR）和/或肌肉特异性酪氨酸激酶（MuSK）的自身抗体血清阴性的重症肌无力，所述方法包括检测 与LRP4结合的自身抗体或其表位。 还包括用于治疗患有神经传递障碍的个体的方法，所述方法包括在体液中检测结合LRP4的单个自身抗体或其表位，并向患者施用有效量的免疫抑制剂和/ 或另一适当的治疗方式。 还包括与LRP4自身抗体结合的抗体和用于检测神经传递或发育障碍的试剂盒。

公开(公告)号：US06969989B1

公开(公告)日：2005-11-29

申请号：US11078266

申请日：2005-03-11

申请人： Lin Mei

发明人： Lin Mei

IPC分类号： G11B5/127 ,  G11B5/187 ,  G11B5/455

CPC分类号： G11B5/1278

摘要： A method characterizes a generally-trapezoidally-shaped portion of a writing pole of a perpendicular magnetic write head in proximity to a magnetic medium. The method includes providing measured track width data corresponding to magnetic track widths of a plurality of tracks written by the writing pole on a rotating magnetic medium underlying the writing pole. The magnetic track widths vary as a function of skew angle of the writing pole during writing. The method further includes determining a magnetic width of the wider of a leading edge and a trailing edge of the writing pole from a first portion of the measured track width data corresponding to a first range of skew angles. The method further includes determining at least one magnetic taper angle of the writing pole from the measured track width data.

摘要翻译： 一种方法表征垂直磁性写头的书写极的大致梯形部分，靠近磁介质。 该方法包括提供对应于写字杆写入的多个轨道的磁道宽度的测量的轨道宽度数据在书写杆下方的旋转磁介质上。 磁道宽度随写入时写字杆的倾斜角度而变化。 所述方法还包括从对应于第一偏斜角范围的所测量的轨道宽度数据的第一部分确定写入极的前边缘和后边缘的较宽的磁宽度。 所述方法还包括根据所测量的轨道宽度数据确定书写杆的至少一个磁锥角。

公开(公告)号：USD990585S1

公开(公告)日：2023-06-27

申请号：US29859130

申请日：2022-11-08

申请人： Lin Mei

设计人： Lin Mei

摘要： FIG. 1 is a front and right perspective view of a LED saber, showing my new design;
FIG. 2 is a rear, left, and bottom perspective view thereof;
FIG. 3 is a front elevational view thereof;
FIG. 4 is a rear elevational view thereof;
FIG. 5 is a left elevational view thereof;
FIG. 6 is a right elevational view thereof;
FIG. 7 is a top plan view thereof;
FIG. 8 is a bottom plan view thereof;
FIG. 9 is an enlarged view of the delineated region 9 in FIG. 1; and,
FIG. 10 is an enlarged view of the delineated region 10 in FIG. 1.
The dot-dash broken lines in FIGS. 1, 9, and 10 form no part of the claimed design and delineated portions of the claimed design that are shown on an enlarged scale in FIGS. 9 and 10. The dashed broken lines in FIGS. 1, 2, 3, 8, and 9 depict portions of the LED saber that form no part of the claimed design.

公开(公告)号：US08524228B2

公开(公告)日：2013-09-03

申请号：US12740594

申请日：2008-11-03

申请人： Wen-Cheng Xiong ,  Jae-Ho Lee ,  Lin Mei

发明人： Wen-Cheng Xiong ,  Jae-Ho Lee ,  Lin Mei

IPC分类号： A61K39/395 ,  A61K39/00 ,  C07K16/22

CPC分类号： A61K38/18 ,  G01N33/689 ,  G01N2333/475 ,  G01N2800/367

摘要： Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.

摘要翻译： 提供男性或女性避孕方法和组合物。 组合物包括有效量的netrin-1以减少或抑制雄性精液中的精子浓度或抑制或减少雄性配子与女性受试者的雌性配子的融合。另一个实施方案提供了一种通过确定雌性不育症的量来确定男性不育症的量 的netrin-1在附睾液或精液样本中的比较，将来自可能的男性的附睾液或精液样品中的netting-1与netrin-1的水平进行比较，其中netrin-1 在男性受试者的样本中，来自可育男性样本中的netrin-1水平高于或低于男性受试者的男性不育症。

公开(公告)号：US20130108616A1

公开(公告)日：2013-05-02

申请号：US13452018

申请日：2012-04-20

申请人： Lin Mei ,  Wen-Cheng Xiong ,  Bin Zhang ,  Changyong Shen

发明人： Lin Mei ,  Wen-Cheng Xiong ,  Bin Zhang ,  Changyong Shen

IPC分类号： G01N33/68

CPC分类号： G01N33/6896 ,  C07K16/28 ,  C07K2317/76 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/564 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/705 ,  G01N2500/04 ,  G01N2800/28 ,  G01N2800/38

摘要： The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

摘要翻译： 本发明包括用于检测神经传递或发育障碍的方法，包括但不限于对乙酰胆碱受体（AChR）和/或肌肉特异性酪氨酸激酶（MuSK）的自身抗体血清阴性的重症肌无力，所述方法包括检测 与LRP4结合的自身抗体或其表位。 还包括用于治疗患有神经传递障碍的个体的方法，所述方法包括在体液中检测结合LRP4的单个自身抗体或其表位，并向患者施用有效量的免疫抑制剂和/ 或另一适当的治疗方式。 还包括与LRP4自身抗体结合的抗体和用于检测神经传递或发育障碍的试剂盒。